Gold prices near 3-week lows as stronger dollar, trade progress weigh
Cathie Wood’s ARK ETFs have disclosed their daily trades for Friday, June 6th, 2025, showcasing a continued focus on the healthcare sector with significant transactions in Veracyte Inc (NASDAQ:VCYT). ARK’s flagship fund, ARKK, purchased 30,771 shares of the genomic diagnostics company, amounting to a substantial investment of $830,201. This move comes on the heels of recent accumulations in Veracyte, signaling ARK’s growing confidence in the firm’s prospects.
In contrast, ARK has trimmed its position in AvidXchange Holdings Inc (NASDAQ:AVDX) by selling 10,025 shares through its ARKF ETF, which focuses on fintech innovation. The total sale value was recorded at $98,044, reflecting a minor reduction in ARK’s exposure to the payment processing technology provider.
Additionally, ARK’s interest in 3D printing technology appears to be waning, as evidenced by the sale of 1,600 shares of 3D Systems Corp (NYSE:DDD) spread across ARKQ and ARKX (NYSE:ARKX) ETFs, dedicated to autonomous technology & robotics and space exploration, respectively. The combined value of these transactions was a modest $2,672.
Looking back at ARK’s trading patterns over the past week, a trend emerges with consistent selling of shares in companies like AvidXchange Holdings Inc (AVDX), Coinbase Global Inc (NASDAQ:COIN), and Palantir Technologies Inc (NYSE:NASDAQ:PLTR). Meanwhile, ARK has shown an accumulating interest in Veracyte Inc (VCYT), with purchases on multiple days, and a notable investment in Guardant Health Inc (NASDAQ:GH) across several sessions.
Investors following ARK’s trading activity should take note of these trends, as they may indicate strategic shifts in the ETFs’ thematic investment approaches. While daily trades offer a snapshot of ARK’s market maneuvers, the ongoing adjustments and reallocations within their portfolios suggest a dynamic response to changing market conditions and long-term conviction in selected sectors and companies.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.